Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eos Energy Enterprises Inc (EOSE) vs Pfizer Inc (PFE) Price & Performance

Eos Energy Enterprises IncTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Eos Energy Enterprises Inc vs Pfizer Inc — how do they compare? Eos Energy Enterprises Inc trades at $4.27 (market cap $1.47B), while Pfizer Inc trades at $26.61 (market cap $154.18B). The key difference: Pfizer Inc is far larger — about 104.9× Eos Energy Enterprises Inc's market cap, and Pfizer Inc pays a 6.36% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals.

EOSEPFE
Market Cap
$1.47B$154.18B
Sector
EnergyHealth
52-Week High
$19.19$28.56
52-Week Low
$3.14$23.60
Enterprise Value
$1.81B$205.67B
Volume
29,869,932
Dividend Yield
6.36%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eos Energy Enterprises Inc

Eos Energy Enterprises (EOSE) trades at $4.15, up 5.33% today, but faces significant financial challenges with a net income margin of -246.76% and negative cash flow from operations. The company reported record Q2 2026 revenue but missed earnings expectations with a $1.20 per share loss. Technical indicators show a mixed picture with bullish overall signals but bearish moving averages, while analyst sentiment remains cautious with 70% hold ratings.

Despite revenue growth potential in the energy storage market, EOSE carries substantial risk due to persistent losses, high debt-to-asset ratio of 91.87%, and ongoing shareholder litigation. The consensus price target of $7.75 suggests upside potential, but investors should weigh the company's financial instability against its growth prospects in the competitive battery storage sector.

Pfizer Inc

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eos Energy Enterprises Inc

Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.

Read more on EOSE

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE